Details

Autor(en) / Beteiligte

• Goh, Yun Shan
• Fong, Siew-Wai
• Hor, Pei Xiang
• Loh, Chiew Yee
• Wang, Bei
• Salleh, Siti Nazihah Mohd
• Ngoh, Eve Zi Xian
• Lee, Raphael Tze Chuen
• Poh, Xuan Ying
• Rao, Suma
• Chia, Po Ying
• Ong, Sean W X
• Lee, Tau Hong
• Lim, Clarissa
• Teo, Jefanie
• Pada, Surinder
• Sun, Louisa Jin
• Ong, Desmond Luan Seng
• Somani, Jyoti
• Lee, Eng Sing
• Maurer-Stroh, Sebastian
• Wang, Cheng-I
• Leo, Yee-Sin
• Lye, David C
• Young, Barnaby Edward
• Ng, Lisa F P
• Renia, Laurent
• Yu, Jocelyn Jin
• Soh, Zheng Kuang
• Chin, Yi Qing
• Lim, Jonathan Jordon
• Ongko, Juwinda
• Libau, Eshele Anak
• Theo, Celine
• Abdullah, Mohammed Ridzwan Bin
• Diong, Shiau Hui
• Yeo, He Ping
• Rouers, Angeline
• Wei, Chang Zi
• Tay, Matthew Zirui
• Torres-Ruesta, Anthony
• Wong, Nathan
• Huang, Yuling
• Ong, Alice Soh Meoy
• Chua, Adeline Chiew Yen
• Nguee, Samantha
• Tan, Yong Jie
• Neo, Vanessa
• Kam, Isaac Kai Jie
• Yadunandan, Ajayanandan
• Selvam, Sooriya Kannan
• Goh, Jarvis
• Ying, Ng Kah
• Yi, Sim Xin
• Lun, Wong Wei
• Loo, Anna Xinyi
• Loo, Liang Hui

Titel

Variant-Specific IgA Protects Against Omicron Infection

Ist Teil von

• The Journal of infectious diseases, 2023-11

Erscheinungsjahr

2023

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background The emergence of rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, coupled with waning vaccine-induced immunity, has contributed to the rise of vaccine breakthrough infections. It is crucial to understand how vaccine-induced protection is mediated. Methods We examined 2 prospective cohorts of mRNA vaccinated and boosted individuals during the Omicron wave of infection in Singapore. Results We found that individuals who remain uninfected over the follow-up period had a higher variant-specific IgA, but not IgG, antibody response at 1 month after booster vaccination, compared with individuals who became infected. Conclusions We conclude that IgA may have a potential contributory role in protection against Omicron infection. Clinical Trials Registration . NCT05142319.